Clinical pharmacokinetics of pregabalin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 50, Issue 8, 2010, Pages 941-950

  Bockbrader, Howard N ^a   Radulovic, Louis L ^a,d   Posvar, Edward L ^a,b   Strand, James C ^a   Alvey, Christine W ^a   Busch, Janice A ^a   Randinitis, Edward J ^a   Corrigan, Brian W ^a   Haig, George M ^a,c   Boyd, Rebecca A ^a   Wesche, David L ^e  

^a PFIZER INC   (United States)

^b AMGEN INC   (United States)

^c ABBOTT LABORATORIES   (United States)

^d Fulcrum Pharma Developments Inc   (United States)

^e MMS Holdings   (United States)

Author keywords

clinical pharmacokinetics; epilepsy; neuropathic pain; Pregabalin

Indexed keywords

PLACEBO; PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ELECTROCARDIOGRAPHY; FOOD INTAKE; HOLTER MONITORING; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; MEAL; MEDICAL HISTORY; MORNING DOSAGE; PHYSICAL EXAMINATION; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOOD DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; URINE;

ADMINISTRATION, ORAL; ADULT; ANALGESICS; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 77953702929     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009352087     Document Type: Article

References (41)

1. Gee NS, Brown JP, Dissanayake VU, Offord J., Thurlow R., Woodruff GN The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996 ; 271: 5768-5776.
2. Dooley DJ, Donovan CM, Pugsley TA Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000 ; 295: 1086-1093.
3. Dooley DJ, Mieske CA, Borosky SA Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000 ; 280: 107-110.
4. Fink K., Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002 ; 42: 229-236.
5. Maneuf YP, Hughes J., McKnight AT Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain. 2001 ; 93: 191-196.
6. Eutamene H., Coelho AM, Theodorou V., et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther. 2000 ; 295: 162-167.
7. Field MJ, Holloman EF, McCleary S., Hughes J., Singh L. Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther. 1997 ; 282: 1242-1246.
8. Field MJ, McCleary S., Hughes J., Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999 ; 80: 391-398.
9. Field MJ, Oles RJ, Lewis AS, McCleary S., Hughes J., Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997 ; 121: 1513-1522.
10. Houghton AK, Lu Y., Westlund KN S-(+)-3-isobutylgaba and its stereoisomer reduces the amount of inflammation and hyperalgesia in an acute arthritis model in the rat. J Pharmacol Exp Ther. 1998 ; 285: 533-538.
11. Jones DL, Sorkin LS Systemic gabapentin and S(+)-3isobutyl-gamma- aminobutyric acid block secondary hyperalgesia. Brain Res. 1998 ; 810: 93-99.
12. Jun JH, Yaksh TL The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg. 1998 ; 86: 348-354.
13. Partridge BJ, Chaplan SR, Sakamoto E., Yaksh TL Characterization of the effects of gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology. 1998 ; 88: 196-205.
14. Taylor CP, Vartanian MG Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models [abstract]. Epilepsia. 1997 ; 38: 35.
15. Taylor CP, Vartanian MG, Yuen PW, Bigge C., Suman-Chauhan N., Hill DR Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 1993 ; 14: 11-15.
16. Williamson J., Lothman E., Taylor C., Bertram E. Comparison of S-(+)-3-isobutyl gaba and gabapentin against kindled hippocampal seizures [abstract]. Epilepsia. 1997 ; 38: 29.
17. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol. 2001 ; 132: 1-4.
18. Freynhagen R., Strojek K., Griesing T., Whalen E., Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005 ; 115: 254-263.
19. Lesser H., Sharma U., LaMoreaux L., Poole RM Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004 ; 63: 2104-2110.
20. Richter RW, Portenoy R., Sharma U., Lamoreaux L., Bockbrader H., Knapp LE Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005 ; 6: 253-260.
21. Rosenstock J., Tuchman M., LaMoreaux L., Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004 ; 110: 628-638.
22. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003 ; 60: 1274-1283.
23. Sabatowski R., Galvez R., Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004 ; 109: 26-35.
24. Arroyo S., Anhut H., Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004 ; 45: 20-27.
25. Beydoun A., Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005 ; 64: 475-480.
26. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 ; 52: 1264-1273.
27. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003 ; 60: 1631-1637.
28. Pohl RB, Feltner DE, Fieve RR, Pande AC Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005 ; 25: 151-158.
29. Windsor BL, Radulovic LL Measurement of a new anticonvulsant, (S)-3-(aminomethyl)-5-methylhexanoic acid, in plasma and milk by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 ; 674: 143-148.
30. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003 ; 23: 240-249.
31. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003 ; 160: 533-540.
32. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 ; 24: 141-149.
33. Rickels K., Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 ; 62: 1022-1030.
34. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 ; 15: 657-680.
35. Corrigan BW, Pool WF, Posvar EL, Radulovic LL, Bockbrader HN Metabolic disposition of pregabalin in healthy volunteers [abstract PI-68]. Clin Phar Ther. 2001 ; 69: 18.
36. Fleisher D., Li C., Zhou Y., Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet. 1999 ; 36: 233-254.
37. Singh BN Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999 ; 37: 213-255.
38. Feng MR, Turluck D., Burleigh J., et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet. 2001 ; 26: 123-128.
39. Diem K, Lentner C, eds. Documenta Geigy, Scientific Tables. 7 th ed. Basel, Switzerland: Ciba-Geigy Limited ; 1972 :518.
40. Radulovic LL, Busch JA, Windsor BL, McNally WP, Sinz MW, Bockbrader HN Pharmacokinetics of the anticonvulsant agent, CI-008, in laboratory animals [abstract]. Pharm Res. 1996 ; 13: S480.
41. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003 ; 43: 277-283.